Trump Medicare drug pricing model may apply to only four companies after exemptions

• The GLOBE price-setting model exempts manufacturers with separate White House deals, leaving only 4 unnamed companies subject to the rule
• Projected Medicare Part B savings plummeted 96% from $11.9 billion in the proposed rule to just $440 million in the final version
• Over two dozen drugmakers including Pfizer, Eli Lilly, and Novo Nordisk signed separate pricing agreements that the White House projects will save governments $64.2 billion over the next decade

Summary: Trump Medicare Drug Pricing Model Significantly Scaled Back

A Trump administration initiative to reduce Medicare hospital drug prices will now apply to only four pharmaceutical companies after exemptions were granted to firms signing separate pricing agreements with the White House, according to a finalized rule published October 1.

Key Details:

The GLOBE price-setting model will exempt manufacturers that secured separate "most favored nation" pricing deals with the administration. While the rule doesn't name the four remaining companies subject to GLOBE, it reveals that over two dozen drugmakers—including industry giants Pfizer, Eli Lilly, and Novo Nordisk—have signed alternative agreements starting last year.

Financial Impact:

The program's projected savings have been dramatically reduced. The Department of Health and Human Services now estimates Medicare Part B spending will decrease by approximately $440 million over the model period, down sharply from the $11.9 billion originally projected in the proposed rule—a reduction of over 96%. HHS did not provide explanation for this substantial downward revision.

Broader Context:

According to the White House Council of Economic Advisers, the overall drug pricing initiative involving the separate agreements could generate combined savings of $64.2 billion over the next decade—$36.6 billion for the federal government and $27.6 billion for state governments.

Market Implications:

The scaled-back approach suggests major pharmaceutical companies successfully negotiated exemptions, limiting the program's scope and potential market disruption. The massive reduction in projected savings raises questions about the program's effectiveness and may indicate weaker negotiating leverage than initially anticipated. Only four smaller manufacturers will face the GLOBE model's pricing constraints.